What is the differential diagnosis and recommended work‑up for a patient presenting with splenomegaly and enlarged kidneys?

Differential Diagnosis and Work-Up for Splenomegaly with Enlarged Kidneys

The combination of splenomegaly and enlarged kidneys should immediately prompt evaluation for plasma cell dyscrasias (particularly multiple myeloma with light-chain deposition disease or AL amyloidosis), followed by myeloproliferative disorders and infiltrative diseases.

Key Differential Diagnoses

The simultaneous presentation of splenomegaly and enlarged kidneys narrows the differential significantly:

Primary Considerations:

• Plasma cell dyscrasias with renal involvement 1, 2:

  • Light-chain deposition disease (LCDD) causing nodular sclerosing glomerulopathy
  • AL amyloidosis with glomerular, interstitial, and vascular involvement
  • Cast nephropathy (though typically doesn't cause kidney enlargement)
  • Multiple myeloma with renal infiltration

• Myeloproliferative disorders 3:

  • Myelofibrosis (can cause massive splenomegaly with secondary renal effects)
  • Chronic myeloid leukemia
  • Polycythemia vera

• Infiltrative diseases 4:

  • Sarcoidosis with multi-organ involvement
  • Gaucher disease
  • Amyloidosis (systemic)

• Lymphoproliferative disorders:

  • Chronic lymphocytic leukemia
  • Lymphoma with renal and splenic involvement

Recommended Initial Work-Up

Laboratory Studies (First-Line):

Hematologic assessment 1, 5:

• Complete blood count with differential (assess for cytopenias, leukocytosis)
• Peripheral blood smear
• Serum protein electrophoresis (SPEP)
• Urine protein electrophoresis (UPEP) with 24-hour collection
• Serum free light chain assay (kappa/lambda ratio)
• Quantitative immunoglobulins (IgG, IgA, IgM)

Renal function and markers 1:

• Serum creatinine and eGFR
• Serum β2-microglobulin (reflects tumor burden)
• Serum lactate dehydrogenase (independent prognostic marker)
• Urinalysis with microscopy

Additional screening:

• Liver function tests
• Hepatitis B and C serology (if liver disease suspected)
• HIV testing (if risk factors present)

Imaging Studies:

Abdominal ultrasonography 5:

• Confirms splenomegaly (normal spleen <13 cm in length)
• Assesses kidney size and echogenicity
• Evaluates for hepatomegaly and portal hypertension
• First-line imaging due to availability and cost-effectiveness

CT abdomen/pelvis with contrast:

• Better characterization of splenic and renal parenchyma
• Identifies lymphadenopathy
• Assesses for masses or infiltrative processes

Tissue Diagnosis:

Renal biopsy with specialized studies 2:

• Light microscopy
• Immunofluorescence (kappa and lambda light chains, IgG, IgA, IgM, C3, C1q)
• Electron microscopy
• Congo red staining for amyloid
• Critical for diagnosing monoclonal immunoglobulin-associated renal diseases

Bone marrow aspiration and biopsy 1:

• Plasma cell percentage and morphology
• Flow cytometry
• FISH studies for high-risk cytogenetics (del 17p, t(4;14), t(14;16))
• Metaphase karyotype

Algorithmic Approach

Step 1: Confirm Organomegaly

• Ultrasound to verify both splenomegaly and bilateral kidney enlargement
• Document spleen size (massive if >20 cm) and kidney dimensions

Step 2: Screen for Plasma Cell Dyscrasia

• SPEP, UPEP, and serum free light chains simultaneously
• If monoclonal protein detected → proceed to bone marrow biopsy and renal biopsy
• This is the most critical pathway given the morbidity/mortality implications 1, 2

Step 3: Hematologic Evaluation

• CBC with smear looking for:
  • Cytopenias (myelofibrosis, infiltrative disease)
  • Leukocytosis with left shift (myeloproliferative disorders)
  • Atypical lymphocytes (lymphoproliferative disorders)

Step 4: Tissue Diagnosis

• Renal biopsy is mandatory if monoclonal protein detected 2
• Bone marrow biopsy if plasma cell dyscrasia or myeloproliferative disorder suspected
• Splenic biopsy rarely needed but consider if diagnosis remains unclear after above workup 6

Critical Pitfalls to Avoid

Do not assume splenomegaly alone explains renal enlargement 3, 7:

• While massive splenomegaly can displace kidneys, it doesn't typically cause true bilateral renal enlargement
• Renal displacement differs from renal enlargement—the former shows normal parenchyma on imaging

Do not delay renal biopsy when monoclonal protein is present 2:

• Light-chain deposition disease and AL amyloidosis require specific immunofluorescence and electron microscopy
• Early diagnosis impacts treatment decisions and prognosis
• Cast nephropathy is a myeloma-defining event requiring immediate intervention

Do not rely on serum creatinine alone 1:

• Renal function may be preserved early in infiltrative diseases
• Proteinuria assessment is essential

Geographic and travel history matters 5:

• Malaria and schistosomiasis cause splenomegaly in up to 80% of people in tropical regions
• Tuberculosis can cause splenic enlargement 6

Prognostic Considerations

If plasma cell dyscrasia is confirmed 1:

• International Staging System (based on β2-microglobulin and albumin)
• Elevated LDH indicates poor prognosis
• FISH abnormalities guide treatment intensity
• Complete response to treatment predicts longer survival

The presence of renal involvement in multiple myeloma significantly impacts treatment decisions and requires nephrology co-management for potential dialysis needs and dose adjustments of chemotherapy.